Showing results (1-10 of 354) with videos related to
Sort By:
Pageof 36
Cancer Chemotherapy and Pharmacology|October 21, 2019
Alternative dosing regimens for atezolizumab: right dose, wrong frequencyDaniel A Goldstein, Mark J RatainClinical Pharmacology and Therapeutics|April 17, 2020
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking ValueAnthony V Serritella, Garth W Strohbehn, Daniel A Goldstein, et al.British Journal of Cancer|August 4, 2023
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategiesAustin Wesevich, Daniel A Goldstein, Koosha Paydary, et al.British Journal of Clinical Pharmacology|May 20, 2020
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitorsCody J Peer, Daniel A Goldstein, Jennifer C Goodell, et al.Cancer Journal (Sudbury, Mass.)|August 1, 2020
Interventional PharmacoeconomicsDaniel A Goldstein, Garth W Strohbehn, Anthony V Serritella, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2018
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No CostMark J RatainNature Reviews. Clinical Oncology|August 6, 2014
Targeted therapies: redefining the primary objective of phase I oncology trialsMark J RatainJournal of Clinical Pharmacology|October 14, 2021
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose DeescalationCody J Peer, Brian L Heiss, Daniel A Goldstein, et al.Pharmacogenomics|December 23, 2006
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotypingFederico Innocenti, Mark J RatainClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Individualizing dosing of irinotecanMark J Ratain, Federico InnocentiPageof 36